Evidence map›Paper›PMID 37060176›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2023

Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial.

Jeong Heo, Ja-Der Liang, Chang Won Kim, Hyun Young Woo, I-Lun Shih, Tung-Hung Su, Zhong-Zhe Lin, So Young Yoo, Stanley Chang, Yasuo Urata and 1 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06686043 (A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06686043 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers

TypeinterventionalSponsorBaylor College of MedicineRan2024 to 2028Enrolled85ConditionsCervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated CarcinomaArmsHPV vaccine, Imiquimod, and metformin combination therapy
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Jeong HeoDepartment of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea. Electronic address: jheo@pusan.ac.kr.
Ja-Der LiangDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chang Won KimDepartment of Radiology, College of Medicine, Pusan National University, Busan, Republic of Korea.
Hyun Young WooDepartment of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
I-Lun ShihDepartment of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan.
Tung-Hung SuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Zhong-Zhe LinDepartment of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
So Young YooBIO-IT Foundry Technology Institute, Pusan National University, Busan, Republic of Korea.
Stanley ChangMedigen Biotechnology Corp., Taipei, Taiwan.
Yasuo UrataOncolys Biopharma Inc., Tokyo, Japan.
Pei-Jer ChenGraduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: peijerchen@ntu.edu.tw.
National Taiwan University Hospital · TWNational Taiwan University · TWPusan National University · KRPusan National University Hospital · KROncolys BioPharma (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBP-301 is an oncolytic adenovirus modified to replicate within cancer cells and lyse them. This open-label, non-comparative, phase I dose-escalation trial aimed to assess its safety and optimal dosage in 20 patients with advanced hepatocellular carcinoma. Good tolerance was shown with a maximum tolerated dose of 6 × 10

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsOncolytic VirotherapyOncolytic VirusesTelomeraseAdenoviridaeCell Line, TumorHumansTelomeraseadvanced hepatocellular carcinomaclinical and translationalhTERT promoterOBP-301oncolytic adenovirussuratodenoturavtelomerase reverse transcriptase genetumor microenvironment

Identifiers

PMID37060176
PMCPMC10362399
OpenAlexW4365517837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.